Spotlighting 3 European Growth Stocks With High Insider Ownership
As European markets face pressure from rising inflation and geopolitical tensions, the pan-European STOXX Europe 600 Index recently saw a decline of 1.66%. In this challenging environment, growth companies with high insider ownership can offer potential resilience, as they often benefit from strong leadership commitment and strategic alignment.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.6% |
| MilDef Group (OM:MILDEF) | 10.3% | 31.1% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 12% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 60.7% |
| CD Projekt Red (WSE:CDR) | 35.2% | 47.9% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 29.8% |
We're going to check out a few of the best picks from our screener tool.
Pharma Mar (BME:PHM)
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company engaged in the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of €1.30 billion.
Operations: Pharma Mar generates its revenue through the creation and global distribution of bio-active oncology products across multiple markets, including Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, and the United States.
Insider Ownership: 12.1%
Pharma Mar's earnings are expected to grow significantly at 39.6% annually over the next three years, outpacing the Spanish market. The company's revenue is also forecast to rise by 20.5% per year, exceeding market averages. Despite a recent drop in net income for H1 2026, Pharma Mar trades well below its estimated fair value and has no substantial insider trading activity reported recently. The ongoing clinical trial for PM54 may impact future growth prospects positively.
- Dive into the specifics of Pharma Mar here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Pharma Mar is trading behind its estimated value.
Banijay Group (ENXTAM:BNJ)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Banijay Group N.V. operates in content production, distribution, online sports betting, and gaming across the United States, Europe, and internationally with a market cap of €3.54 billion.
Operations: The company generates revenue from Entertainment and Live (€3.23 billion) and Sports Betting and Gaming (€2.02 billion) segments.
Insider Ownership: 10.1%
Banijay Group's earnings are forecast to grow significantly at 26.82% annually, surpassing the Dutch market average. Despite a recent decline in net income for H1 2026, Banijay trades substantially below its estimated fair value. The company recently completed a merger with All3Media, enhancing its global media presence and securing €801 million in cash proceeds. Antoine Jouteau's appointment as CEO of Banijay Gaming aims to accelerate growth and strengthen innovation across regulated markets.
- Get an in-depth perspective on Banijay Group's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Banijay Group's share price might be on the cheaper side.
Swedencare (OM:SECARE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Swedencare AB (publ) develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses across North America, Europe, and internationally with a market cap of approximately SEK3.73 billion.
Operations: The company's revenue is derived from segments including Europe (SEK702.30 million), Production (SEK688.80 million), and North America (SEK1.58 billion).
Insider Ownership: 12.8%
Swedencare's earnings are projected to grow significantly at 45.79% annually, outpacing the Swedish market average. Recent financial results show a positive turnaround with a net income of SEK 23.7 million for Q2 2026, compared to a loss the previous year. Insiders have been buying shares modestly over the last three months. Despite trading well below its estimated fair value, Swedencare's revenue growth is slower than its earnings trajectory and expected market performance.
- Take a closer look at Swedencare's potential here in our earnings growth report.
- Our valuation report here indicates Swedencare may be undervalued.
Seize The Opportunity
- Discover the full array of 216 Fast Growing European Companies With High Insider Ownership right here.
- Curious About Other Options? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com